AbbVie posts Crohn's OLE results; registers Phase 3 lung cancer and Phase 1 glabellar lines trials
Three AbbVie trial updates this week span a completed Crohn's disease extension study with new results and two newly posted early-stage trials.
AbbVie's registry activity this week included one completed study with newly posted results and two new trial postings at earlier stages.
- A long-term open-label extension study of upadacitinib (RINVOQ, ABT-494) in Crohn's disease is now marked completed, with results first posted, after enrolling 107 participants in a non-randomized Phase 2 design.1 The study measured the percentage of participants achieving endoscopic remission at Month 12, based on the Simplified Endoscopic Score for Crohn's Disease.1
- AbbVie has started recruiting for a Phase 1 study testing sequential injections of investigational drug AGN-151586 followed by BOTOX (onabotulinumtoxinA) for glabellar lines. The trial plans to enroll approximately 120 adult participants with moderate to severe glabellar lines across approximately 8 sites in the United States.2
- A new Phase 3 trial comparing IV ABBV-1480 plus chemotherapy against pembrolizumab plus chemotherapy in non-small cell lung cancer is listed as not yet recruiting. The study plans to enroll up to approximately 940 adult participants with locally advanced or metastatic squamous NSCLC across approximately 250 sites globally3, with progression-free survival assessed by blinded independent central review per RECIST v1.1 as one primary outcome.3
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.